No Data
Shu Taishen: 2024 Annual Report
Shu Taishen: 2024 Annual Report Summary
Last year's loss narrowed mainly due to cutting R&D? Staidson's performance remains under pressure | Interpretations
① In 2024, Staidson's total revenue has declined again, and the loss continues, with the company having incurred losses for five consecutive years so far. ② During the reporting period, the company's R&D investment was 0.162 billion yuan, a decrease of 63.77% compared to the same period last year, with most major R&D projects in early clinical trial stages.
Staidson (300204.SZ) announces its 2024 annual performance, with a net loss attributable to the parent company of 0.145 billion yuan, narrowing by 63.69%.
Staidson (300204.SZ) released its annual report for 2024, with revenue of 0.325 billion yuan, ...
GTJA: Continuous iteration of anti-tumor therapies, domestic new drugs welcome breakthroughs.
GTJA focuses on products with significant differentiation advantages and leading companies in innovative segments.
Staidson (300204.SZ): SanNuoJiaYi has been recognized as a national high-tech enterprise.
Glory Exchange February 13th丨Staidson (300204.SZ) announced that the company's subsidiary Peking San Nuo Jia Yi Biotechnology Co., Ltd. (referred to as "San Nuo Jia Yi") recently received the "High-tech Enterprise Certificate" jointly issued by the Peking Municipal Science and Technology Commission, the Peking Municipal Finance Bureau, and the State Taxation Administration of Peking. San Nuo Jia Yi has passed the recognition as a high-tech enterprise. In 2024, San Nuo Jia Yi successfully passed the recognition as a high-tech enterprise and recently obtained the "High-tech Enterprise Certificate" with certificate number GR202411007668, issued on December 3, 2024.